Published in Vaccine Weekly, March 9th, 1998
These ZADAXIN marketing approvals are SciClone's first in Latin America and the company's first outside Asia. ZADAXIN is already marketed in three Asian countries - the People's Republic of China, the Philippines and Singapore. SciClone has filed for approval to market ZADAXIN in 16 additional countries in Asia, the Middle East and Latin America.
Consistent with SciClone's strategic plan to enter Argentina, a lead market in Latin America, as rapidly as possible, ZADAXIN...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly